Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 1;181(2):284-287.
doi: 10.1001/jamainternmed.2020.5017.

Prolonged Increases in Public-Payer Spending and Prices After Unapproved Drug Initiative Approval of Colchicine

Natalie McCormick  1 , Zachary S Wallace  1 , Chio Yokose  1 , April Jorge  1 , Chana A Sacks  2 , John Hsu  3 , Hyon K Choi  1
Affiliations

Prolonged Increases in Public-Payer Spending and Prices After Unapproved Drug Initiative Approval of Colchicine

Natalie McCormick et al. JAMA Intern Med. .

Abstract

This cohort study examines national Medicaid and Medicare drug-spending data to examine colchicine prices over the period from 2008 to 2017.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr McCormick reported grants from Canadian Institutes of Health Research during the conduct of the study. Dr Hsu reported grants from the National Institutes of Health; consulting fees from USC, Community Servings, Delta Health Alliance, DaVita, and Sidley Austin LLP; and grant reviews from Columbia University and the American Association for the Advancement of Science outside the submitted work. Dr Choi reported grants from National Institute of Arthritis and Musculoskeletal and Skin Diseases during the conduct of the study, grants and personal fees from Ironwood and Horizon, and personal fees from Selecta, Takeda, Kowa, and Vaxart outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Mean Annual Drug Unit Prices for Each Colchicine Formulation Available Before, During, and After Colcrys’s July 2009 Approval and Period of Market Exclusivity for Acute Gout by Program
A, Medicare data (dashed lines) only available from 2012 onward. B, Total annual Medicaid spending for all colchicine products marketed during the study period.
See this image and copyright information in PMC

Comment in

  • The Colchicine Debacle Revisited.
    Guglielmo BJ. Guglielmo BJ. JAMA Intern Med. 2021 Feb 1;181(2):287-288. doi: 10.1001/jamainternmed.2020.5044. JAMA Intern Med. 2021. PMID: 33252611 No abstract available.

References

    1. Tardif J-C, Kouz S, Waters DD, et al. . Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497-2505. doi:10.1056/NEJMoa1912388 - DOI - PubMed
    1. Guglielmo BJ The colchicine debacle. JAMA Intern Med. 2013;173(3):184-185. doi:10.1001/jamainternmed.2013.1405 - DOI - PubMed
    1. Congressional Budget Office. Background paper: factors underlying the growth in Medicare’s spending for physicians’ services. June 2007. Accessed October 27, 2020. https://www.cbo.gov/publication/18726
    1. Hwang TJ, Jain N, Lauffenburger JC, Vokinger KN, Kesselheim AS. Analysis of proposed Medicare Part B to Part D shift with associated changes in total spending and patient cost-sharing for prescription drugs. JAMA Intern Med. 2019;179(3):374-380. doi:10.1001/jamainternmed.2018.6417 - DOI - PMC - PubMed
    1. Kesselheim AS, Franklin JM, Kim SC, Seeger JD, Solomon DH. Reductions in use of colchicine after FDA enforcement of market exclusivity in a commercially insured population. J Gen Intern Med. 2015;30(11):1633-1638. doi:10.1007/s11606-015-3285-7 - DOI - PMC - PubMed